BioSpace News Archive

Mereo BioPharma Group plc announced that data from the Phase 2 “ASTRAEUS” trial of alvelestat for the treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease, as well as post-hoc analyses demonstrating the association between biomarker reductions with alvelestat and improvements in SGRQ were presented for the first time to the scientific community at the 2023 American Thoracic Society International Conference.

EnCompass Technologies, Inc. announced its novel F2 cerebral embolic filter was used successfully in three transcatheter aortic valve replacement procedures on April 29th and 30th at the Israeli-Georgian Medical Research Clinic, Tbilisi, Georgia.

The EROS study is the first real-world evidence analysis of BREZTRI in more than 2,400 patients with COPD from a claims database registry, and was presented as a late-breaking abstract at the ATS 2023 International Conference in Washington, DC, hosted by the American Thoracic Society.

Atrion Corporation announced that its Board of Directors declared a quarterly dividend of $2.15 per share on its outstanding shares of Common Stock.

Tampa General Hospital, one of the nation’s top 10 transplant centers, wrote a new chapter in its history earlier this month with its first living donor liver transplant, which also is the first such surgery on Florida’s west coast.

The U.S. Food and Drug Administration approved Brixadi extended-release injection for subcutaneous use to treat moderate to severe opioid use disorder.

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was dosed in GALARISSO, the Phase 2 dermatomyositis (DM) trial with GLPG3667.

MDxHealth SA, a commercial-stage precision diagnostics company, announced that Michael McGarrity, Chief Executive Officer, will present at William Blair’s 43rd Annual Growth Stock Conference on Thursday, June 8, 2023, at 1:00pm ET.

Assembly Biosciences, Inc. announced that Jason Okazaki, chief executive officer and president, and William Delaney, PhD, chief scientific officer, will present in a fireside chat during the 2023 Jefferies Healthcare Conference at 4:00 p.m. Eastern Time on June 7, 2023.

Ardelyx, Inc. announced that on May 22, 2023, the compensation committee of the company’s board of directors granted two new non-executive employees options to purchase an aggregate of 114,038 shares of the company’s common stock, and granted five new non-executive employees an aggregate of 68,700 Restricted Stock Units.